Zenas Biopharma Inc ZBIO

$28.01 +0.37 (1.34%)

Valuation

Market cap
1,874,490,000
Revenue TTM
$10,000,000
Net income TTM
$-377,740,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
-3,777.40%
Debt to equity
0.83

Trading

Volume
304,800
Avg volume
607,518
Day's range
$26.89 – $28.18
Shares out
67,818,000
Stochastic %K
52%
Beta
-0.88
Analysts
Strong Buy
Price target
$47.88

Price

Company profile

Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc?RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus eryt...

Show more

Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc?RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus. The company develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a CTLA-4-Ig fusion protein designed to have an extended half-life versus; and ZB001, an anti-IGF-1R monoclonal antibody. The company was formerly known as Zenas BioPharma (Cayman) Limited and changed its name to Zenas BioPharma, Inc. in August 2023. The company was incorporated in 2019 and is headquartered in Waltham, Massachusetts.

Industry
Biotechnology
Sector
Healthcare
Phone
857 271 2954
Website
https://zenasbio.com
Address
852 Winter Street, Suite 250, Waltham, United States

Latest news

Stocktwits

Merlintrader Nov 11, 7:08 AM
$ZBIO Zenas BioPharma (ZBIO): Q3 net loss $108.9M, cash $647.1M Free weekly catalyst newsletter: https://merlintrader.beehiiv.com/p/week-ahead-10-catalysts-we-re-watching-november-9-13 Not investment advice.
0 replies
GTA_Terminal Nov 9, 2:25 AM
Unusual options activity in $ZBIO. Money on both sides, which usually means traders expect a move but don't agree on the direction. Look up any stock's options flow and dark pools on the GTA Terminal, free for 7 days: https://globaltradersacademy.com/start-trial?a=stocktwits&sym=ZBIO&utm_source=stocktwits&utm_medium=social&utm_campaign=trial&utm_content=ZBIO Read the full article for the full details: https://globaltradersacademy.com/articles/zbio-technical-levels-options-flow-mixed-between-27-19-and-28-98?utm_source=stocktwits&utm_medium=social
0 replies
Merlintrader Nov 5, 4:58 PM
$ZBIO Zenas BioPharma Q3 2026 (reported Nov 5): Cash, equivalents and investments $647.1M at Sept 30; Q3 net loss $108.9M; Obexelimab IgG4-RD BLA under FDA review; target action date May 27, 2027; EMA marketing application validated; SunStone lupus topline and initial ZB021 data guided to Q4 2026. Questions worth checking: What is the next catalyst for ZBIO stock? When is the FDA decision on Zenas obexelimab? How much cash does ZBIO have and how long could it last? Answers, primary sources and downloadable PDF report in our hub: https://www.merlintrader.com/zenas-biopharma-stock-hub/?utm_source=stocktwits&utm_medium=social&utm_campaign=zbio_hubpdf_nov26 Not investment advice.
0 replies
NVDAMillionaire Nov 2, 10:01 AM
$ZBIO Brilliant piece that captures ZBIO's situation perfectly. So if you want to update your understanding of ZBIO or get to know ZBIO better, this is essential reading. https://everyticker.com/quote/ZBIO/analysis/zenas-biopharma-a-binary-bet-on-obexelimab-with-geopolitical-supply-chain-risks-nasdaq-zbio
0 replies
Quantumup Oct 28, 10:41 AM
Citi added $ZBIO (Buy-$48) to its Upside 90-Day Catalyst Watch List—believes the SunStone readout in systemic lupus erythematosus (SLE) in Q4 is well positioned to hit the primary endpoint.
0 replies
chole1 Oct 27, 1:47 PM
$ZBIO Novartis calling its BTKinhibitor probably biggest ever drug... where will ZBIO trade if its own BTKinh reports positive P3 results? Lets see if safety holds up, that would be massive
0 replies
Merlintrader Oct 22, 7:46 PM
$ZBIO Latest analyst update, Oct 20, 2026: Morgan Stanley resumed coverage of Zenas BioPharma at Equal-Weight with a 32 USD target (third-party opinion). The FDA decision on obexelimab in IgG4-related disease is set for May 27, 2027. Full hub (obexelimab, PDUFA, cash): https://www.merlintrader.com/zenas-biopharma-stock-hub/ Not investment advice.
1 replies
mahaljs Oct 19, 4:55 PM
$ZBIO
0 replies